Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yale, J-F, Bakris, G, Cariou, B, Yue, D, David-Neto, E, Xi, L, Figueroa, K, Wajs, E, Usiskin, K, Meininger, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654568/
https://www.ncbi.nlm.nih.gov/pubmed/23464594
http://dx.doi.org/10.1111/dom.12090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654568/
https://www.ncbi.nlm.nih.gov/pubmed/23464594
http://dx.doi.org/10.1111/dom.12090

Ejemplares similares